P I Industries Ltd
P I Industries Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #19 of 23 in Fertilizers & Agrochemicals
See the sector's top 10 — free with your mobile number.
The short version
Management expects continued growth with positive revenue growth in FY27, targeting late single-digit to early double-digit growth depending on global conditions. Management expects growth in FY27, with revenue growth likely in late single-digit to early double-digit range, subject to global uncertainties.
From P I Industries Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Management expects continued growth with positive revenue growth in FY27, targeting late single-digit to early double-digit growth depending on global conditions.
- New molecules in the CSM segment contributed 18%-20% to portfolio and are growing faster despite overall market challenges.
- Electronic chemicals business is at an early stage, with potential to build into a substantial INR 500 crore+ opportunity in 4-5 years.
- Pharma segment aims to reach INR 500-600 crore topline in 2-3 years, which could lead to EBITDA positivity afterward.
- Biological nematode product shows strong growth potential, particularly in Brazil and Mexico, with US launch underway and expected scale-up over next 2-3 years.
2 more points from P I Industries Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what P I Industries Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- PI Industries plans to invest an additional few hundred crore INR in electronic chemicals and fine chemicals, with a target of around INR 500 crore, considered a substantial investment for growth in these new areas.
- The company expects consistent capex of INR 700 to INR 800 crore for manufacturing expansions, new product launches, and R&D across both pharma and agrochemical businesses.
- Over the last three years, PI incurred nearly INR 2,600 crore in capex, spanning capacity ramp-up, technology development, and new product arenas with longer gestation like NCEs and pharma capabilities.
- FY27 will see heavy investments focused on market-building, product launches (e.g., Pioxaniliprole), and regulatory compliance costs for global filings.
2 more points from P I Industries Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Fertilizers & Agrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what P I Industries Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
P I Industries Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.6K Cr, net profit ₹200 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What P I Industries Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Fertilizers & Agrochemicals this season
- Rama Phosphates (Q4 FY26)
Revenue grew by 20% year-on-year (Page 8). Key investor presentation takeaways from Rama Phosphates's Q4 FY26 investor presentation — and how it ranks against s
- Khaitan Chemical (Q4 FY26)
Q4-FY26 Operational Revenue: INR 1,930 million, up 20.1% YoY (from INR 1,607 million in Q4-FY25). Key investor presentation takeaways from Khaitan Chemical's Q4
- Dhansa Labs (Q4 FY26)
120-140 crores in additional annual revenue upon stabilization, with initial revenue of around Rs. Key concall takeaways from Dhansa Labs's Q4 FY26 earnings…
- Advance Agrolife (Q4 FY26)
Q4 FY26 total revenue: ₹1,259.07 million, up 40% YoY (Page 24). Key concall takeaways from Advance Agrolife Ltd's Q4 FY26 earnings call — and how it ranks…
Potential multibaggers · Q2 FY27
Potential multibaggers in Fertilizers & Agrochemicals
on management's own guidance
- Dharmaj CropGood growth2
- Anya Polytech &Good growth1
- M B Agro Prod.Good growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
P I Industries Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were P I Industries Ltd Q4 FY26 results?
Management expects continued growth with positive revenue growth in FY27, targeting late single-digit to early double-digit growth depending on global conditions. Management expects growth in FY27, with revenue growth likely in late single-digit to early double-digit range, subject to global uncertainties.
What is P I Industries Ltd share price analysis?
P I Industries Ltd currently shows a neutral. The stock trades at a P/E of 35.5 with a market cap of ₹42,633 Cr. Investors should review the full earnings analysis for detailed insights.
Is P I Industries Ltd planning capital expenditure?
PI Industries plans to invest an additional few hundred crore INR in electronic chemicals and fine chemicals, with a target of around INR 500 crore, considered a substantial investment for growth in these new areas.
Keep P I Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
